|MDACC Study No:||2010-0696 (clinicaltrials.gov NCT No: NCT01199367)|
|Title:||A phase I/II study to evaluate the safety, tolerability, and preliminary efficacy of KW-2450 in combination with lapatinib and letrozole in subjects with advanced or metastatic breast cancer whose tumor overexpress HER2|
|Principal Investigator:||Naoto Ueno|
|Treatment Agent:||KW-2450; Lapatinib; Letrozole|
|Study Description:||The goal of Phase 1 of this clinical research study is to find the highest |
tolerable dose of KW-2450 when given in combination with lapatinib and
letrozole to patients with advanced breast cancer. The safety of this drug
combination will also be studied.